Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Multicenter Extension Study for Continued Access to Roche/Genentech Cancer Therapies
2023-504263-16-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of atezolizumab, entrectinib, bevacizumab, lenvatinib, ipatasertib and 6 more in cancer and Neoplasm, sponsored by Roche. Primary endpoint: Number of Participants with Continued Access to Roche IMP(s)-Based Therapy and/or Comparator Agent(s). Planned start Jan 2024; status: authorised.
02
Drugs
atezolizumabentrectinibbevacizumablenvatinibipatasertib
03
Conditions
cancerNeoplasm
Beyond the preview
Go deeper on 2023-504263-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504263-16-00.